Therapeutic Targeting of Tumor Suppressor Genes

Overview

Journal Cancer

Publisher Wiley

Specialty Oncology

Date 2015 Jan 6

PMID 25557041

Citations 86

Authors

Luc G T Morris

Timothy A Chan

Affiliations

Soon will be listed here.

Abstract

Carcinogenesis is a multistep process attributable to both gain-of-function mutations in oncogenes and loss-of-function mutations in tumor suppressor genes. Currently, most molecular targeted therapies are inhibitors of oncogenes, because inactivated tumor suppressor genes have proven harder to "drug." Nevertheless, in cancers, tumor suppressor genes undergo alteration more frequently than do oncogenes. In recent years, several promising strategies directed at tumor suppressor genes, or the pathways controlled by these genes, have emerged. Here, we describe advances in a number of different methodologies aimed at therapeutically targeting tumors driven by inactivated tumor suppressor genes.

Citing Articles

A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins.

Ganesan I, Kiyokawa H Cancers (Basel). 2025; 17(4).

PMID: 40002221 PMC: 11853300. DOI: 10.3390/cancers17040626.

Positive Selection Shapes Breast Cancer Tumor Suppressor Genes: Unveiling Insights into BRCA1, BRCA2, and MDC1 Stability.

Fadel Y, Khaled M, Emam M, Marzouk N, Sobih S, Abd-Elaty H J Mol Evol. 2024; 93(1):100-110.

PMID: 39681652 DOI: 10.1007/s00239-024-10222-8.

Mapping in silico genetic networks of the KMT2D tumour suppressor gene to uncover novel functional associations and cancer cell vulnerabilities.

Takemon Y, Pleasance E, Gagliardi A, Hughes C, Csizmok V, Wee K Genome Med. 2024; 16(1):136.

PMID: 39578878 PMC: 11583415. DOI: 10.1186/s13073-024-01401-9.

The present and future of the Cancer Dependency Map.

Arafeh R, Shibue T, Dempster J, Hahn W, Vazquez F Nat Rev Cancer. 2024; 25(1):59-73.

PMID: 39468210 DOI: 10.1038/s41568-024-00763-x.

Biomarkers From Discovery to Clinical Application: In Silico Pre-Clinical Validation Approach in the Face of Lung Cancer.

Kori M, Gov E, Arga K, Sinha R Biomark Insights. 2024; 19:11772719241287400.

PMID: 39371614 PMC: 11452870. DOI: 10.1177/11772719241287400.

References

Hollstein M, Sidransky D, Vogelstein B, Harris C . p53 mutations in human cancers. Science. 1991; 253(5015):49-53. DOI: 10.1126/science.1905840. View

Morrison A, Johnson A, Johnston L, Sugino A . Pathway correcting DNA replication errors in Saccharomyces cerevisiae. EMBO J. 1993; 12(4):1467-73. PMC: 413358. DOI: 10.1002/j.1460-2075.1993.tb05790.x. View

Kussie P, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine A . Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996; 274(5289):948-53. DOI: 10.1126/science.274.5289.948. View

Kinzler K, Vogelstein B . Cancer-susceptibility genes. Gatekeepers and caretakers. Nature. 1997; 386(6627):761, 763. DOI: 10.1038/386761a0. View

Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff D, Kirn D . ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997; 3(6):639-45. DOI: 10.1038/nm0697-639. View

Datta S, Dudek H, Tao X, Masters S, Fu H, Gotoh Y . Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997; 91(2):231-41. DOI: 10.1016/s0092-8674(00)80405-5. View

Teng D, Hu R, Lin H, Davis T, Iliev D, Frye C . MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res. 1997; 57(23):5221-5. View

Schuler M, Rochlitz C, Horowitz J, Schlegel J, Perruchoud A, Kommoss F . A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. Hum Gene Ther. 1998; 9(14):2075-82. DOI: 10.1089/hum.1998.9.14-2075. View

Stambolic V, Suzuki A, de la Pompa J, Brothers G, Mirtsos C, Sasaki T . Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998; 95(1):29-39. DOI: 10.1016/s0092-8674(00)81780-8. View

10.

Myers M, Pass I, Batty I, van der Kaay J, Stolarov J, Hemmings B . The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A. 1998; 95(23):13513-8. PMC: 24850. DOI: 10.1073/pnas.95.23.13513. View

11.

Swisher S, Roth J, Nemunaitis J, LAWRENCE D, Kemp B, Carrasco C . Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999; 91(9):763-71. DOI: 10.1093/jnci/91.9.763. View

12.

Issa J . CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004; 4(12):988-93. DOI: 10.1038/nrc1507. View

13.

Lang G, Iwakuma T, Suh Y, Liu G, Rao V, Parant J . Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004; 119(6):861-72. DOI: 10.1016/j.cell.2004.11.006. View

14.

Puc J, Keniry M, Li H, Pandita T, Choudhury A, Memeo L . Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell. 2005; 7(2):193-204. DOI: 10.1016/j.ccr.2005.01.009. View

15.

Bryant H, Schultz N, Thomas H, Parker K, Flower D, Lopez E . Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035):913-7. DOI: 10.1038/nature03443. View

16.

Zhao Y, Thomas H, Batey M, Cowell I, Richardson C, Griffin R . Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res. 2006; 66(10):5354-62. DOI: 10.1158/0008-5472.CAN-05-4275. View

17.

Wang H, Han H, Mousses S, Von Hoff D . Targeting loss-of-function mutations in tumor-suppressor genes as a strategy for development of cancer therapeutic agents. Semin Oncol. 2006; 33(4):513-20. DOI: 10.1053/j.seminoncol.2006.04.013. View

18.

Christophorou M, Ringshausen I, Finch A, Swigart L, Evan G . The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature. 2006; 443(7108):214-7. DOI: 10.1038/nature05077. View

19.

Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C . Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2006; 109(1):31-9. PMC: 1785068. DOI: 10.1182/blood-2006-06-025999. View

20.

Xue W, Zender L, Miething C, Dickins R, Hernando E, Krizhanovsky V . Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007; 445(7128):656-60. PMC: 4601097. DOI: 10.1038/nature05529. View